3.64% -1.5042

Anaptysbio Inc (ANAB)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Anaptysbio Inc Stock (ANAB) Company Profile

Anaptysbio Inc

858-362-6295

10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA

Prossima data di guadagno

Ultimi documenti SEC

ANAB's Discussions on Twitter

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-05-22	Aggiornamento	JP Morgan	Underweight → Neutral
2023-05-18	Iniziato	TD Cowen	Outperform
2023-01-06	Downgrade	Raymond James	Outperform → Mkt Perform
2022-11-01	Aggiornamento	Guggenheim	Neutral → Buy
2022-09-19	Ripresa	H.C. Wainwright	Buy
2022-09-13	Downgrade	Truist	Buy → Hold
2022-09-01	Iniziato	Raymond James	Outperform
2022-03-22	Downgrade	Guggenheim	Buy → Neutral
2021-06-22	Iniziato	H.C. Wainwright	Buy
2021-05-21	Iniziato	UBS	Neutral
2021-03-16	Aggiornamento	Truist	Hold → Buy
2021-03-09	Downgrade	Wedbush	Outperform → Neutral
2021-03-08	Downgrade	JP Morgan	Overweight → Underweight
2021-02-11	Aggiornamento	JP Morgan	Underweight → Overweight
2020-10-27	Aggiornamento	Wedbush	Neutral → Outperform
2020-10-14	Aggiornamento	Guggenheim	Neutral → Buy
2019-11-08	Downgrade	JP Morgan	Overweight → Underweight
2019-11-08	Downgrade	Jefferies	Buy → Hold
2019-11-08	Downgrade	SunTrust	Buy → Hold
2019-11-08	Downgrade	Wedbush	Outperform → Neutral
2019-06-21	Downgrade	Credit Suisse	Outperform → Neutral
2019-06-21	Downgrade	Stifel	Buy → Hold
2018-12-20	Iniziato	H.C. Wainwright	Buy
2018-11-21	Iniziato	JP Morgan	Overweight
2018-07-19	Iniziato	Credit Suisse	Outperform
2018-04-04	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2018-03-27	Reiterato	Stifel	Buy
2018-03-06	Reiterato	Stifel	Buy
2018-02-15	Reiterato	SunTrust	Buy
2018-01-23	Reiterato	Credit Suisse	Outperform
2017-11-15	Iniziato	SunTrust	Buy
2017-11-09	Iniziato	Jefferies	Buy
2017-10-11	Reiterato	RBC Capital Mkts	Outperform
2017-09-15	Iniziato	RBC Capital Mkts	Outperform

Mostra tutto

Anaptysbio Inc Borsa (ANAB) Ultime notizie

Anaptysbio Inc Azioni (ANAB) Dati Finanziari

Anaptysbio Inc Azioni (ANAB) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Lizzul Paul F.	Chief Medical Officer	Aug 14 '24	Sale	40.00	2,000	80,000	11,618
EcoR1 Capital, LLC	10% Owner	Aug 14 '24	Buy	36.50	273,972	9,999,978	7,794,996

Anaptysbio Inc (ANAB)

Anaptysbio Inc Stock (ANAB) Company Profile

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Anaptysbio Inc Borsa (ANAB) Ultime notizie

TD Asset Management Inc Raises Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

A Guide To The Risks Of Investing In AnaptysBio Inc (ANAB) - Knox Daily

Bioventus Inc [BVS] stock for 683,736 USD was bought by Bartholdson John A. - Knox Daily

Insider Selling: Lizzul Paul F., AnaptysBio Inc [ANAB] Chief Medical Officer divested 2,000 shares - Knox Daily

BTIG Reiterates Buy Rating on Anaptysbio (ANAB) (correction) - StreetInsider.com

AnaptysBio (NASDAQ:ANAB) Shares Down 3.2% - MarketBeat

Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $50.30 - MarketBeat

AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Learn to Evaluate (ANAB) using the Charts - Stock Traders Daily

Anaptys Announces Participation in September Investor Conferences - ForexTV.com

Anaptys Announces Participation in September Investor Conferences - Yahoo Finance UK

Anaptys Announces Participation in September Investor Conferences - StockTitan

Why AnaptysBio Was Such a Healthy Stock This Week - sharewise

Why AnaptysBio Was Such a Healthy Stock This Week - Yahoo Finance

Alopecia Areata Clinical Trials 2024: FDA Approvals, Pipeline, - openPR

Contrasting AstraZeneca (NASDAQ:AZN) & AnaptysBio (NASDAQ:ANAB) - Defense World

AnaptysBio Inc (ANAB) receives a Buy rating from H.C. Wainwright - Knoxdaily.com

Hedge Fund and Insider Trading News: Carl Icahn, Ken Griffin, Warren Buffett, Engaged Capital, Elliott Management, Oslo Asset Management, AnaptysBio Inc (ANAB), and More - Insider Monkey

Guggenheim maintains buy on AnaptysBio shares, cites ANAB032 potential By Investing.com - Investing.com Canada

Insiders Buying Yum China And 2 Other Stocks - Benzinga

AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by California State Teachers Retirement System - Defense World

Short Interest in AnaptysBio, Inc. (NASDAQ:ANAB) Rises By 9.3% - Defense World

Ecor1 Capital, Llc Buys 273,972 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock - Defense World

AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by Assenagon Asset Management S.A. - MarketBeat

Assenagon Asset Management S.A. Has $7.68 Million Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World

AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Update - MarketBeat

Anaptysbio chief medical officer executes stock transactions By Investing.com - Investing.com Australia

Truist Financial Increases AnaptysBio (NASDAQ:ANAB) Price Target to $30.00 - Defense World

AnaptysBio, Inc. to Post Q3 2024 Earnings of ($1.57) Per Share, HC Wainwright Forecasts (NASDAQ:ANAB) - Defense World

AnaptysBio (NASDAQ:ANAB) Stock Price Up 6.6% After Insider Buying Activity - Defense World

AnaptysBio, Inc. (NASDAQ:ANAB) Major Shareholder Ecor1 Capital, Llc Acquires 273,972 Shares - MarketBeat

Public Equity Report: AnaptysBio, Avidity draw nine-digit offerings - BioCentury

Anaptysbio chief medical officer executes stock transactions By Investing.com - Investing.com Canada

Anaptysbio chief medical officer executes stock transactions By Investing.com - Investing.com UK

AnaptysBio (NASDAQ:ANAB) Trading Up 6.6% Following Insider Buying Activity - MarketBeat

Q3 2024 Earnings Forecast for AnaptysBio, Inc. Issued By HC Wainwright (NASDAQ:ANAB) - MarketBeat

Nothing is Better Than AnaptysBio Inc (ANAB) stock at the moment - SETE News

AnaptysBio (NASDAQ:ANAB) Reaches New 12-Month High at $41.11 - Defense World

Metric Analysis: AnaptysBio Inc (ANAB)’s Key Ratios in the Limelight - The Dwinnex

AnaptysBio (NASDAQ:ANAB) Stock Price Down 4.6% - MarketBeat

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point (NASDAQ:ANAB) - Seeking Alpha

AnaptysBio shares hold rating; price target raised on pipeline programs By Investing.com - Investing.com Canada

AnaptysBio’s (ANAB) Buy Rating Reaffirmed at HC Wainwright - Defense World

AnaptysBio shares hold rating; price target raised on pipeline programs By Investing.com - Investing.com UK

AnaptysBio (NASDAQ:ANAB) Price Target Raised to $30.00 - MarketBeat

AnaptysBio announces pricing of $100 million offering - The Pharma Letter

ANAB’s Financial Health: Exploring AnaptysBio Inc’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle

AnaptysBio (NASDAQ:ANAB) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

AnaptysBio Inc [ANAB] stock was sold by Lizzul Paul F. at the price of US$52500.0 - Knox Daily

AnaptysBio stock soars to 52-week high, hits $38.91 By Investing.com - Investing.com Canada

AnaptysBio (NASDAQ:ANAB) Sets New 12-Month High at $41.11 - MarketBeat

Anaptysbio Inc Azioni (ANAB) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Anaptysbio Inc Azioni (ANAB) insider trading

Simile a ANAB